[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:brca2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BRCA2 Gene",61,48,[8,16,23,29,36,42,48,55,61,67,73,79,85,91,97,103,109,115,121,127,132,138,143,149,155,162,168,174,180,186,192,198,204,209,215,221,227,233,239,245,251,257,263,269,275,281,287,293,299,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06236139","Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.748678Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[20],"Phase 2","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT03990896","Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",[20],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:29.705241Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04150042","SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells",[33],"Phase 1","2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.297862Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04858334","APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",[20],"2026-08-26T02:15:52.238965Z","2026-05-05T02:43:29.056915Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06267729","Study of AZD0754 in Participants With Metastatic Prostate Cancer",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.077996Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT06380751","Saruparib (AZD5305) Plus Camizestrant Compared With CDK4\u002F6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+\u002F ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",[52],"Phase 3","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.920406Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[33],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06177171","Olaparib and ASTX727 in BRCA1\u002F2- and Homologous Recombination Deficient (HRD)-Mutated Tumors",[33],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:27.676733Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06488378","Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1\u002F2 and PALB2- Associated Metastatic HER2-negative Breast Cancer",[33],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.482798Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05806515","Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation",[20],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.295281Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06952803","A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT\u002FADT in Men With High-risk Prostate Cancer With a BRCA Mutation",[52],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:26.975819Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[20],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05694715","Combination Therapy in Cancers With Mutations in DNA Repair Genes",[33],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:28.876459Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06458712","Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",[33],"2026-08-26T02:15:51.395565Z","2026-07-24T01:27:14.872137Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[12],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT04890613","Study of CX-5461 in Patients With Solid Tumours and BRCA1\u002F2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",[33],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:27.067991Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05287451","Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study",[],"2026-08-26T02:15:44.309045Z","2026-07-05T05:32:16.798306Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT04294927","TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention",[],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:27.631193Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":59,"content_modified":131},"NCT04913064","Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer",[],"2026-05-05T02:43:27.487085Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05013216","Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",[33],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:26.738998Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":113,"content_modified":142},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[20],"2026-07-19T19:36:05.126907Z",{"nct_id":144,"title":145,"phases":146,"status":13,"updated_at":147,"content_modified":148},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[20],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT05384535","Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort",[],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:28.342933Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":160,"content_modified":161},"NCT06122896","Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals",[159],"Early Phase 1","2026-08-26T02:17:13.277148Z","2026-05-05T02:43:27.075591Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT03729115","A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer",[],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:26.901351Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study",[52],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.641158Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT04494945","Identifying and Caring for Individuals With Inherited Cancer Syndrome",[],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.687767Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT07612046","A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening",[],"2026-08-26T02:16:27.227548Z","2026-07-19T19:36:05.076756Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT03396341","Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes",[],"2026-08-26T02:16:12.203827Z","2026-07-05T05:32:16.770025Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":59,"content_modified":208},"NCT06888388","Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer",[],"2026-05-13T02:55:06.588403Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT06271291","Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts",[],"2026-08-26T02:18:36.226508Z","2026-05-13T02:55:06.430707Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":219,"content_modified":220},"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.292506Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":225,"content_modified":226},"NCT05058846","Pilot Study of Pancreatic Cancer Screening",[],"2026-08-03T02:54:15.542480Z","2026-05-13T02:55:06.282505Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT05006131","Pancreatic Cancer Screening for At-risk Individuals",[],"2026-08-26T02:17:12.307088Z","2026-05-13T02:55:06.277680Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT03805919","Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:15:18.897219Z","2026-05-13T02:55:06.177945Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT03250078","A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals",[],"2026-08-26T02:16:58.658552Z","2026-05-13T02:55:06.120432Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT02478892","Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk",[],"2026-08-26T02:19:21.761002Z","2026-05-13T02:55:06.095979Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT07564141","Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer",[52],"2026-08-26T02:16:39.977107Z","2026-07-19T19:36:05.140343Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT04970056","Pancreatic Cancer Early Detection Consortium",[],"2026-08-26T02:15:04.877798Z","2026-05-13T02:55:06.276618Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT01102556","PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease",[],"2026-08-26T02:19:07.104270Z","2026-05-13T02:55:06.068743Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT00823654","Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations",[],"2026-08-26T02:17:28.381459Z","2026-05-13T02:55:06.066613Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT02775461","Pancreas Registry and High Risk Registry",[],"2026-08-26T02:15:27.567165Z","2026-05-13T02:55:06.101947Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT01034033","Genetic & Pathological Studies of BRCA1\u002FBRCA2: Associated Tumors & Blood Samples",[],"2026-08-26T02:19:30.857183Z","2026-05-13T02:55:06.066896Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT04038502","Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.505079Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT06972719","Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy",[],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:28.715509Z",{"nct_id":300,"title":301,"phases":302,"status":303,"updated_at":304,"content_modified":305},"NCT07565155","Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:15.642947Z","2026-05-13T02:55:06.729176Z",{"nct_id":307,"title":308,"phases":309,"status":303,"updated_at":310,"content_modified":311},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[20],"2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z"]